GEN News Highlights

AskBio, Genzyme Ink Gene Therapy Cross-Licensing Agreement

(Page
1
of
1)

Asklepios BioPharmaceutical (AskBio) this week said it had entered into a non-exclusive licensing agreement, through which the firm is granting Genzyme rights to its Duplex gene therapy vector technology.

AskBio said its technology enables a gene therapy adeno-associated viral (AAV) vector “to package and deliver more potent therapeutic DNA cargo to a patient's cells.” Genzyme will be using the Duplex technology for internal product development.

Additionally, Genzyme is granting AskBio rights to its Intra-Strand Base-Pairing technology, which the firm will use to support the packaging of DNA within an AAV-based gene therapy vector.

“The rights obtained from Genzyme by AskBio strengthen and broaden the basis with which AskBio may continue its use and sublicense of Duplex vectors for internal clinical development, as well as external partnerships and collaborations,” AskBio said.

Financial terms of this cross-licensing deal were not disclosed.

"We appreciate the collaborative approach with which both companies entered into this cross-license, and believe it broadly strengthens the value potential for future advancements within the field of AAV gene therapy,” AskBio vp Jade Samulski said in a statement. “This cross-license with Genzyme represents our ninth license of the Duplex vectors, and further validates AskBio's platform of vector technologies, and their significance and potential for future patient benefit.”

Added Sam Wadsworth, head of gene therapy R&D at Genzyme: “We believe our efforts will be enhanced through AskBio's technology, as we continue to pursue targeted solutions to address unmet medical needs.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

38.9%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

22.2%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.